CRP test endorsed
This article was originally published in The Gray Sheet
Executive Summary
American Heart Association and CDC recommend high-sensitivity C-reactive protein testing as an option to facilitate heart disease risk assessment and potential treatment selection when other factors project a 10-year CHD risk of 10%-20%. Published in the Jan. 28 issue of Circulation, guidelines suggest additional studies of the systemic inflammation marker test are needed to clarify appropriate use. A recent 28,000-patient study by Paul Ridker, MD, Brigham and Women's Hospital, Boston, et al., showed the roughly $20 CRP test is a stronger predictor of cardiovascular events than LDL cholesterol ("The Gray Sheet" Nov. 18, 2002, In Brief). CRP test product makers include Bayer, Beckman Coulter, Dade Behring and Diagnostic Products...
You may also be interested in...
Heart health marker
C-reactive protein is a stronger predictor of cardiovascular events than low-density lipoprotein (LDL) cholesterol, according to a study led by Paul Ridker, MD, Brigham and Women's Hospital in Boston, reported in the Nov. 14 issue of the New England Journal of Medicine. The study followed 27,939 apparently healthy American women for eight years, correlating LDL cholesterol and C-reactive protein levels to incidence of myocardial infarction, ischemic stroke, coronary revascularization and cardiovascular-related death...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.